These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 24187110

  • 1. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.
    Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, Yamanaka H.
    J Rheumatol; 2014 Jan; 41(1):15-23. PubMed ID: 24187110
    [Abstract] [Full Text] [Related]

  • 2. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan.
    Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, Tomobe M, Totsuka K.
    J Rheumatol; 2015 Aug; 42(8):1368-75. PubMed ID: 26034149
    [Abstract] [Full Text] [Related]

  • 3. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T, Fujio K, Yamaoka K, Tomobe M, Kuroyanagi K, Kameda H.
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
    Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, Yamanaka H.
    Mod Rheumatol; 2017 Mar; 27(2):217-226. PubMed ID: 27414105
    [Abstract] [Full Text] [Related]

  • 5. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
    Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, Van Vollenhoven R.
    J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
    [Abstract] [Full Text] [Related]

  • 6. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.
    Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, Yamanaka H.
    Ann Rheum Dis; 2011 Dec; 70(12):2148-51. PubMed ID: 21852254
    [Abstract] [Full Text] [Related]

  • 7. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
    Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y.
    Mod Rheumatol; 2010 Aug; 20(4):343-52. PubMed ID: 20480201
    [Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
    Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Tanaka Y.
    Mod Rheumatol; 2012 Aug; 22(4):498-508. PubMed ID: 21993918
    [Abstract] [Full Text] [Related]

  • 9. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
    Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota S.
    Ann Rheum Dis; 2016 Sep; 75(9):1654-60. PubMed ID: 26644233
    [Abstract] [Full Text] [Related]

  • 10. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
    Iking-Konert C, von Hinüber U, Richter C, Schwenke H, Gürtler I, Kästner P, Klapperich B, Peters MA, Burmester GR.
    Rheumatology (Oxford); 2016 Apr; 55(4):624-35. PubMed ID: 26515959
    [Abstract] [Full Text] [Related]

  • 11. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources.
    Curtis JR, Perez-Gutthann S, Suissa S, Napalkov P, Singh N, Thompson L, Porter-Brown B, Actemra Pharmacoepidemiology Board.
    Semin Arthritis Rheum; 2015 Feb; 44(4):381-8. PubMed ID: 25300699
    [Abstract] [Full Text] [Related]

  • 12. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, Takeuchi T.
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [Abstract] [Full Text] [Related]

  • 13. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [Abstract] [Full Text] [Related]

  • 14. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
    Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N.
    Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice.
    Kaneko A, Hirano Y, Fujibayashi T, Hattori Y, Terabe K, Kojima T, Ishiguro N.
    Mod Rheumatol; 2013 May; 23(3):466-77. PubMed ID: 22895833
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.
    Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Haruna S, Ushida N, Kawana K, Tanaka Y.
    Mod Rheumatol; 2014 May; 24(3):390-8. PubMed ID: 24252049
    [Abstract] [Full Text] [Related]

  • 18. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.
    Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M.
    J Rheumatol; 2009 May; 36(5):898-906. PubMed ID: 19332630
    [Abstract] [Full Text] [Related]

  • 19. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF, Qushmaq K, Aljishi F.
    Ann Saudi Med; 2016 May; 36(3):190-6. PubMed ID: 27236390
    [Abstract] [Full Text] [Related]

  • 20. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J.
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.